T. Rowe Price Associates
PDSB icon

T. Rowe Price Associates’s PDS Biotechnology PDSB Stock Holding History

T. Rowe Price Associates’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,263
Closed -$33K – 3098
2025
Q2 		$33K Sell
24,263
-637
-3% -$865 ﹤0.01% 3034
2025
Q1 		$30K Hold
24,900
– – ﹤0.01% 2986
2024
Q4 		$41K Hold
24,900
– – ﹤0.01% 2960
2024
Q3 		$96K Hold
24,900
– – ﹤0.01% 2827
2024
Q2 		$73K Buy
24,900
+7,361
+42% +$23.6K ﹤0.01% 2796
2024
Q1 		$70K Buy
17,539
+1,786
+11% +$9.2K ﹤0.01% 2833
2023
Q4 		$79K Buy
15,753
+1,166
+8% +$5.8K ﹤0.01% 2743
2023
Q3 		$74K Hold
14,587
– – ﹤0.01% 2714
2023
Q2 		$74K Buy
+14,587
New +$95.5K ﹤0.01% 2749

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's PDSB Position: Q3 2025 in Review

T. Rowe Price Associates sold out of PDS Biotechnology (PDSB) in Q3 2025, closing a stake of 24,263 shares — an estimated $33K sold.

T. Rowe Price Associates first reported a position in PDSB in Q2 2023 and held it in 9 quarters. The position peaked at $96K in Q3 2024. 47 funds tracked by Wall St. Rank hold PDSB as of Q3 2025.

  • T. Rowe Price Associates reported no remaining PDS Biotechnology position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 24,263 PDS Biotechnology shares in Q3 2025, an estimated $33K.
  • T. Rowe Price Associates first reported a position in PDS Biotechnology in Q2 2023 and held it in 9 quarters.
  • T. Rowe Price Associates's PDS Biotechnology position peaked at $96K in Q3 2024.
  • 47 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2025.

Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.